<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082480</url>
  </required_header>
  <id_info>
    <org_study_id>RDCT-TWDH</org_study_id>
    <nct_id>NCT05082480</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of the Use of a Novel Crosslinking Hyaluronan Hydrogel on the Prevention of the Adhesion Occurrence After Trigger Finger Release Surgery</brief_title>
  <official_title>A Prospective, Randomized, Evaluator/Subject-blinded, Control Clinical Study: to Evaluate the Effectiveness of the Use of a Novel Crosslinking Hyaluronan Hydrogel on the Prevention of the Adhesion Occurrence After Trigger Finger Release Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SciVision Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SciVision Biotech Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Effectiveness of the use of a Novel Crosslinking Hyaluronan Hydrogel on the&#xD;
      Prevention of the Adhesion Occurrence After Trigger Finger Release Surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of Total Active Motion (TAM) score for target finger.</measure>
    <time_frame>30 days post-operation</time_frame>
    <description>The percentage of Total Active Motion (TAM) score for target finger at 30 days post-operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of TAM score of target finger.</measure>
    <time_frame>baseline, 14, 60, 90, and 180 days post-operation</time_frame>
    <description>The percentage of TAM score of target finger at baseline, 14, 60, 90, and 180 days post-operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAM score of target finger.</measure>
    <time_frame>baseline, 14, 30, 60, 90, and 180 days post-operation</time_frame>
    <description>TAM score of target finger at baseline, 14, 30, 60, 90, and 180 days post-operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The grade of TAM score of target finger and contralateral finger.</measure>
    <time_frame>baseline, 14, 30, 60, 90, and 180 days post-operation</time_frame>
    <description>The grade of TAM score of target finger and contralateral finger at baseline, 14, 30, 60, 90, and 180 days post-operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects self-evaluating Visual Analogue Scale (VAS) in pain of target finger at baseline, 14, 30, 60, 90, and 180 days post-operation.</measure>
    <time_frame>baseline, 14, 30, 60, 90, and 180 days post-operation</time_frame>
    <description>Subjects self-evaluating Visual Analogue Scale (VAS) in pain of target finger at baseline, 14, 30, 60, 90, and 180 days post-operation. The VAS scale uses a 100 mm line labelled at '0' with 'no pain' and '100' with 'worst pain'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects self-evaluating Quick Disabilities of the Arm, Shoulder and Hand Score (Quick-Dash).</measure>
    <time_frame>baseline, 14, 30, 60, 90, and 180 days post-operation</time_frame>
    <description>Subjects self-evaluating Quick Disabilities of the Arm, Shoulder and Hand Score (Quick-Dash) at baseline, 14, 30, 60, 90, and 180 days post-operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of tendon by sonography.</measure>
    <time_frame>baseline, 14, 30, 60, 90, and 180 days post-operation</time_frame>
    <description>The evaluation of tendon by sonography at baseline, 14, 30, 60, 90, and 180 days post-operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects self-evaluating Visual Analogue Scale (VAS) in satisfaction</measure>
    <time_frame>14, 30, 60, 90, and 180 days post-operation</time_frame>
    <description>Subjects self-evaluating satisfaction at 14, 30, 60, 90, and 180 days post-operation. Patients rate their treatment satisfaction based on a 100 mm VAS. The VAS scale uses a 100 mm line labelled at '0' with 'least satisfaction' and '100' with 'highest satisfaction'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence, severity and correlation of adverse event (AE) and serious adverse event (SAE).</measure>
    <time_frame>baseline, 14, 30, 60, 90, and 180 days post-operation</time_frame>
    <description>The incidence, severity and correlation of adverse event (AE) and serious adverse event (SAE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Trigger Finger</condition>
  <condition>Hyaluronic Acid</condition>
  <arm_group>
    <arm_group_label>Hyaluronic acid (HA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyaluronic acid (HA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid (HA)</intervention_name>
    <description>Hyaluronic acid (HA)</description>
    <arm_group_label>Hyaluronic acid (HA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Agree to participate in this study and sign informed consent form&#xD;
&#xD;
          2. Age 20 to 65 years of male or female&#xD;
&#xD;
          3. The trigger finger, except thumb, classified as 3 to 4 points and plan to conduct&#xD;
             trigger finger release surgery;&#xD;
&#xD;
          4. The trigger finger, except thumb, classified as 2 points with the symptom of flexion&#xD;
             contracture and plan to conduct trigger finger release surgery;&#xD;
&#xD;
          5. Agree to comply with the follow-up schedule of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target finger with other adhesion in tendon, joint, or proximal nerve, compression&#xD;
             injury or other disease;&#xD;
&#xD;
          2. Contralateral finger with other adhesion in tendon, joint, or proximal nerve, or&#xD;
             compression injury;&#xD;
&#xD;
          3. The operation site was conducted tendon transplantation or any surgery in past 6&#xD;
             months;&#xD;
&#xD;
          4. Receiving orthopedic-related treatment which may affect the evaluation of the study;&#xD;
&#xD;
          5. The skin of the operation site with infection, deficiency, or needing skin&#xD;
             transplantation;&#xD;
&#xD;
          6. With poorly controlled chronic diseases, such as diabetes mellitus;&#xD;
&#xD;
          7. Patient with autoimmune disease (such as rheumatoid arthritis), malignant tumors,&#xD;
             coagulation diseases, heart diseases, mental diseases, etc., may cause patients to&#xD;
             participate in the trial at higher risk;&#xD;
&#xD;
          8. Patient who has taken cortisol within the past 6 months, systemic corticosteroids&#xD;
             within the past 2 months, immunosuppressive drugs within past 3 months, or&#xD;
             non-steroidal anti-inflammatory drugs (NSAIDs) everyday within 1 week or NSAIDs within&#xD;
             8 hours occasionally. (subjects who have received inhaled/intranasal corticosteroids&#xD;
             could be considered to include.);&#xD;
&#xD;
          9. With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or&#xD;
             taking blood circulation promotion and blood stasis removement medications within the&#xD;
             past 10 days;&#xD;
&#xD;
         10. With history of hypersensitivity or allergy to hyaluronic acid or any component of the&#xD;
             device; With history of hypersensitivity or allergy to Gram-positive bacteria or&#xD;
             Streptococcus proteins; other severe hypersensitivity history unsuitable for&#xD;
             participating in the study;&#xD;
&#xD;
         11. Pregnant, planning pregnancy or in breastfeeding females;&#xD;
&#xD;
         12. Other circumstances which judged to be unsuitable for participating in the study by&#xD;
             the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yin-Chih Fu, MD,PhD</last_name>
    <phone>+886-7-3121101</phone>
    <phone_ext>5751</phone_ext>
    <email>microfu@gmail.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trigger Finger Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

